STOCK TITAN

Avanos Medical Inc - AVNS STOCK NEWS

Welcome to our dedicated news page for Avanos Medical (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avanos Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avanos Medical's position in the market.

Rhea-AI Summary
Avanos Medical, Inc. (AVNS) voluntarily recalls specific lots of MIC Gastric – Jejunal Feeding Tube Kits in response to Nurse Assist, LLC's recall of pre-filled syringes. The kits contain syringes crucial for inflating the retention balloon of the feeding tube.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
Rhea-AI Summary
Avanos Medical, Inc. reports fourth quarter and full-year 2023 results, highlighting a decrease in net sales but positive outlook for 2024. The company completed a transformation initiative, divested its respiratory health business, and acquired Diros Technology, Inc. Financially, there was a decrease in net sales, diluted earnings per share, and free cash flow in 2023. However, the company expects organic growth in 2024 with adjusted gross profit margins and earnings per share projections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
-
Rhea-AI Summary
Avanos Medical, Inc. (AVNS) will discuss its financial results and business highlights for Q4 and full year 2023 in a webcast on Feb. 20, 2024. The call will feature CEO Joe Woody and CFO Michael Greiner.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
conferences earnings
Rhea-AI Summary
Avanos Medical, Inc. (AVNS) reports unaudited preliminary financial results for Q4 2023, with net sales expected to be in the range of $170-173 million, a decrease of 6.5-4.5% compared to the same period in 2022. The company also revised its preliminary revenue outlook for 2024, expecting net sales in the range of $685-705 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.23%
Tags
-
Rhea-AI Summary
Avanos Medical, Inc. (NYSE: AVNS) CEO to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
conferences
-
Rhea-AI Summary
Avanos Medical, Inc. (NYSE: AVNS) to participate in analyst-led fireside chat at Stifel 2023 Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
conferences
Rhea-AI Summary
Avanos Medical, Inc. reported third quarter 2023 financial results, with total net sales of $171.3 million, a decrease of 0.6% compared to the prior year period. The company experienced a net loss of $8.8 million from continuing operations for the quarter. However, adjusted net income from continuing operations totaled $14.0 million, compared to $11.5 million a year ago. Avanos completed the sale of assets related to its RH business and closed the acquisition of Diros Technology, Inc. as part of its three-year transformation initiative. The company anticipates revenue between $675 million and $685 million for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.24%
Tags
-
Rhea-AI Summary
Avanos Medical, Inc. will webcast its conference call discussing financial results for Q3 2023 on Nov. 1. The call will be hosted by CEO Joe Woody and CFO Michael Greiner. Details for joining the call and accessing the webcast are provided in the PR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
conferences earnings
-
Rhea-AI Summary
AirLife completes acquisition of Avanos Medical's respiratory health business, adding three complementary brands and two manufacturing facilities to its platform. The transaction advances AirLife's strategy to enhance its portfolio and serve more customers as a one-stop source for consumable breathing solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
Rhea-AI Summary
Avanos Medical CFO to participate in fireside chat at CL King's conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences
Avanos Medical Inc

NYSE:AVNS

AVNS Rankings

AVNS Stock Data

861.71M
39.28M
2.84%
99.42%
2.56%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Alpharetta

About AVNS

avanos is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter.headquartered in alpharetta, georgia, avanos is committed to creating the next generation of innovative healthcare solutions which will address our most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery.avanos develops, manufactures and markets its recognized brands in more than 90 countries.